Fig. 6: Progression-free survival (PFS) and overall survival (OS) in patients with DLBCL treated with rituximab plus chemotherapy from a local cohort stratified according to GCB/ABC cell-of-origin, IPI status, MYC or BCL2 expression and combined MYC/BCL2 expression.
From: Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma
Survival curves for 104 patients from the local cohort stratified according to a GCB or ABC cell-of-origin determined by the random forest predictor, b IPI status, c MYC status determined by gene expression profiling, d BCL2 status determined by gene expression profiling, or e combined MYC/BCL2 double expression status.
